Prostate cancer is the most commonly diagnosed malignancy and is the third leading cause of cancer death among men in developed countries. In the United States alone, an estimated 242,000 men were diagnosed with prostate cancer in 2012 and 28,000 died from their disease. Despite its high incidence and mortality, few risk factors have so far been identified for prostate cancer beyond increasing age, a family history of prostate cancer, certain genetic polymorphisms or mutations, living in a Western nation and African descent. Being of Asian descent is protective for prostate cancer. Prostate cancer treatment is dominated by strategies to control androgen receptor (AR) activity. AR has an impact on prostate cancer development through the regulation of not only transcription networks but also genomic stability and DNA repair, as manifest in the emergence of gene fusions. Therapeutically, the major focus of drug development is therefore to reduce androgen levels; for example, with inhibitors of androgen synthesis, such as abiraterone, or with antagonists that prevent androgen binding to AR, for example, enzalutamide or bicalutamide. These therapies confer survival advantages for patients with metastatic disease, but prostate cancer is nonetheless lethal once progression has occurred.
Personalizing the use of cancer therapeutics is the major focus of current biomedical research. Low molecular weight inhibitors of protein kinases represent a very attractive family of cancer drugs based on multiple observations that cancer cells have elevated kinase activity to enhance proliferation, migration and invasion, but also to maintain apoptosis resistance. Polo-like kinases (Plks) represent a family of very attractive drug targets. In a broad phylogenetic context Plks are master regulators of mitotic progression, involved in the regulation of mitotic entry, the metaphase-toanaphase transition, and mitotic exit. A major question relates to the mechanism by which Plk1 regulates AR signaling. Recent investigations revealed that the microtubulestabilizing drug paclitaxel, which is commonly used for the treatment of prostate cancer, inhibits signaling from the androgen receptor by inhibiting its nuclear accumulation downstream of microtubule stabilization. In this context, Plk1 suppresses kinetochore-microtubule dynamics to stabilize initial attachments in prometaphase. An excellent recent study by the Liu lab relates Plk1 activity directly to the functional regulation of spindle components. However, additional mechanisms should also be considered: Recent studies by Raab and colleagues have indentified novel targets of BI2536 other than Plk1. 6 Moreover, acetylation of lysine residues is a post-translational modification with broad relevance to cellular signaling and disease biology. Enzymes that 'write' (histone acetyltransferases, HATs) and 'erase' (histone deacetylases, HDACs) acetylation sites are an area of extensive research in current drug development. The principal readers of e-N-acetyl lysine (Kac) marks are bromodomains (BRDs), which are a diverse family of evolutionary conserved protein-interaction modules. Recently, studies on 2 inhibitors that target BRDs of the BET (bromodomains and extra-terminal) family provided compelling data supporting targeting of these BRDs in inflammation and in an aggressive type of squamous cell carcinoma. Furthermore, it was demonstrated that BI2536 targets the aminoterminal bromodomains of BRD4 and most interestingly BI2536 has the ability to displace BRD4 from chromatin. A new study revealed that AR-signaling-competent human CRPC cell lines are preferentially sensitive to BET inhibition. 7 BRD4 binds with the N-terminal domain of AR and can be disrupted by the BRD4 inhibitor JQ1. Since BI2536 also modulates the function of BRD4, it should be considered that this could be also a mode of action of BI2536 for the downregulation of AR signaling. Taken together, the clinical dual kinase-bromodomain inhibitor BI2536 seems to be a potent and selective drug with polypharmacologies anticipated to add important therapeutic benefit for the treatment of prostate cancer patients.
